Related Experiment Video
Updated: Aug 23, 2025
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Role of surgery in high-grade neuroendocrine tumors of the lung
Mehmet Ali Bedirhan1, Nur Ürer2, Yunus Seyrek3
1Department of Chest Disease, University of Health Sciences, Yedikule Training and Research Hospital for Chest Diseases and Thoracic Surgery, Istanbul, Türkiye.
Background:
This study aims to evaluate the surgical results for high-grade neuroendocrine carcinomas and to identify factors that influence prognosis.
Methods:
Between January 2009 and December 2017, a total of 71 patients (58 males, 13 females; mean age: 62±9.6 years; range, 38 to 78 years) with a high-grade neuroendocrine carcinoma of the lung were retrospectively analyzed. Overall survival and five-year overall survival rates were evaluated.
Results:
The mean overall survival was 60.7±6.9 months with a five-year survival rate of 44.3%. The mean overall survival and five-year overall survival rates according to disease stage were as follows: Stage 1, 67±10.8 months (46%); Stage 2, 61.4±10.8 months (45%); and Stage 3, 33.2±8.6 months (32%) (p=0.02). The mean overall survival and five-year overall survival rate according to histological types were as follows: in large cell neuroendocrine carcinoma, 59.4±9.2 months (45%); in small cell neuroendocrine carcinoma, 68.6±12.2 months (43%); and in combined-type neuroendocrine carcinoma, 40.9±10.1 months (35%) (p=0.34).
Conclusion:
Thoracic surgeons should be very selective in performing pulmonary resection in patients with Stage 3 high-grade neuroendocrine carcinomas and combined cell subtype tumors.
